Similar companies
Income Statement (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 71.3B | 4.8% |
| Gross Profit | 60B | 3.8% |
| Cost of Revenue | 11.3B | 10.1% |
| Operating expense | 26.2B | 17.8% |
| Net Income | 27.3B | 36.2% |
| EBITDA | 37.4B | 7.4% |
Balance Sheet (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 397B | 7.6% |
| Total Liabilities | 277B | 7.8% |
| Total Equity | 121B | 7.1% |
| Shares Outstanding | 4.45B | 0.3% |
Cash Flow (NONE)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 43.9B | 13.2% |
| Cash from financing | -18.4B | 210.3% |
Financial Highlights for Novo Nordisk in Q3 '24
Novo Nordisk reported a revenue of 71.3B, which is a 4.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 60B, marking a 3.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 11.3B, a 10.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 26.2B, showing a -17.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 27.3B, showing a 36.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 37.4B, showing a 7.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Novo Nordisk with growth in revenue, gross profit, and net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
